Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John T Isaacs

Showing results (1-10 of 134) with videos related to

Pageof 14
Sort By:
American Journal of Clinical and Experimental Urology|April 19, 2018
Resolving the Coffey Paradox: what does the androgen receptor do in normal vs. malignant prostate epithelial cells?John T Isaacs
Expert Opinion on Investigational Drugs|September 15, 2010
The long and winding road for the development of tasquinimod as an oral second-generation quinoline-3-carboxamide antiangiogenic drug for the treatment of prostate cancerJohn T Isaacs
BJU International|December 20, 2005
New strategies for the medical treatment of prostate cancerJohn T Isaacs
The American Journal of Pathology|February 22, 2015
Lessons learned about prostatic transformation from the age-related methylation of 5α-reductase type 2 geneJohn T Isaacs
The Prostate|April 4, 2008
Prostate stem cells and benign prostatic hyperplasiaJohn T Isaacs
Oncotarget|September 22, 2018
Checks and balances occur not only in government, but also in biologyJohn T Isaacs
American Journal of Clinical and Experimental Urology|July 13, 2023
Consequence of evolutionary loss of seasonal breeding by humans for prostate cancer chemopreventionJohn T Isaacs
Science (New York, N.Y.)|July 13, 2013
Cancer. Prostate cancer takes nerveJohn T Isaacs
Cancer Cell|October 11, 2017
Cellular Origin of Androgen Receptor Pathway-Independent Prostate Cancer and Implications for TherapyW Nathaniel Brennen, John T Isaacs
Oncotarget|April 28, 2011
The "infectious" nature of human prostate cancer: a cautionary noteKaren S Sfanos, John T Isaacs
Pageof 14

Showing results (1-10 of 134) with videos related to

Sort By:
Pageof 14
American Journal of Clinical and Experimental Urology|April 19, 2018
Resolving the Coffey Paradox: what does the androgen receptor do in normal vs. malignant prostate epithelial cells?John T Isaacs
Expert Opinion on Investigational Drugs|September 15, 2010
The long and winding road for the development of tasquinimod as an oral second-generation quinoline-3-carboxamide antiangiogenic drug for the treatment of prostate cancerJohn T Isaacs
BJU International|December 20, 2005
New strategies for the medical treatment of prostate cancerJohn T Isaacs
The American Journal of Pathology|February 22, 2015
Lessons learned about prostatic transformation from the age-related methylation of 5α-reductase type 2 geneJohn T Isaacs
The Prostate|April 4, 2008
Prostate stem cells and benign prostatic hyperplasiaJohn T Isaacs
Oncotarget|September 22, 2018
Checks and balances occur not only in government, but also in biologyJohn T Isaacs
American Journal of Clinical and Experimental Urology|July 13, 2023
Consequence of evolutionary loss of seasonal breeding by humans for prostate cancer chemopreventionJohn T Isaacs
Science (New York, N.Y.)|July 13, 2013
Cancer. Prostate cancer takes nerveJohn T Isaacs
Cancer Cell|October 11, 2017
Cellular Origin of Androgen Receptor Pathway-Independent Prostate Cancer and Implications for TherapyW Nathaniel Brennen, John T Isaacs
Oncotarget|April 28, 2011
The "infectious" nature of human prostate cancer: a cautionary noteKaren S Sfanos, John T Isaacs
Pageof 14